WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Faculty

Juliana Schwaab, MD

Internal Medicine Specialist
Department of Hematology and Oncology
University Hospital Mannheim
Heidelberg University
Mannheim, Germany

Disclosures

No relevant financial relationships

Karl Sotlar, MD

Professor
Institute of Pathology
University Hospital Salzburg
Paracelsus Medical University
Salzburg, Austria

Disclosures

No relevant financial relationships

Deepti H. Radia, MD

Consultant Hematologist
Department of Clinical Haematology
Guy’s & St. Thomas NHS Foundation Trust
London, UK

Disclosures

Consultant or advisor for: Blueprint; Cogent; Novartis
Speaker or member of speakers bureau for: Blueprint; Cogent; Novartis
Research funding from: Blueprint

Editor

Keisha Peters, MSc

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Keisha Peters, MSc, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CPD

Systemic Mastocytosis (SM): Diagnostic Challenges and Treatment Optimization for Advanced SM

Authors: Juliana Schwaab, MD; Karl Sotlar, MD; Deepti H. Radia, MD
CPD Released: 4/22/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/22/2023, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US oncology team members, including hematologists/oncologists, pathologists, and other oncology clinicians practicing across Europe.

The goal of this activity is for the learner to increase their knowledge of the diagnosis and management of advanced systemic mastocytosis (SM).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Challenges in diagnosis of patients with advanced SM
- Accurate diagnosis using biochemical and molecular disease characterization
Have greater competence related to
- Select appropriate therapy for a patient with advanced SM based upon disease characterization and risk stratification

Disclosures

Faculty

Juliana Schwaab, MD

Internal Medicine Specialist
Department of Hematology and Oncology
University Hospital Mannheim
Heidelberg University
Mannheim, Germany

Disclosures

No relevant financial relationships

Karl Sotlar, MD

Professor
Institute of Pathology
University Hospital Salzburg
Paracelsus Medical University
Salzburg, Austria

Disclosures

No relevant financial relationships

Deepti H. Radia, MD

Consultant Hematologist
Department of Clinical Haematology
Guy’s & St. Thomas NHS Foundation Trust
London, UK

Disclosures

Consultant or advisor for: Blueprint; Cogent; Novartis
Speaker or member of speakers bureau for: Blueprint; Cogent; Novartis
Research funding from: Blueprint

Editor

Keisha Peters, MSc

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Keisha Peters, MSc, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Systemic Mastocytosis (SM): Diagnostic Challenges and Treatment Optimization for Advanced SM

Authors: Juliana Schwaab, MD; Karl Sotlar, MD; Deepti H. Radia, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 4/22/2022

Valid for credit through: 4/22/2023, 11:59 PM EST

processing....

Select Any Chapter to Begin

Did you know that patients with SM report worse mental and physical component scores compared to lung cancer patients?

Page 1 of 29

Systemic Mastocytosis: Disease Overview and Pathogenesis - Pre-Assessment

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of WebMD Global, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Juliana Schwaab, MD

Karl Sotlar, MD

Deepti H. Radia, MD

Editor

Keisha Peters, MSc

Compliance Reviewer

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Peer Reviewer

CPD

Systemic Mastocytosis (SM): Diagnostic Challenges and Treatment Optimization for Advanced SM

Target Audience and Goal Statement

Disclosures

Faculty

Juliana Schwaab, MD

Karl Sotlar, MD

Deepti H. Radia, MD

Editor

Keisha Peters, MSc

Compliance Reviewer

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Systemic Mastocytosis (SM): Diagnostic Challenges and Treatment Optimization for Advanced SM

Select Any Chapter to Begin

Did you know that patients with SM report worse mental and physical component scores compared to lung cancer patients?